Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

1.65
-0.0300-1.79%
Post-market: 1.680.0300+1.82%18:16 EDT
Volume:76.53K
Turnover:124.95K
Market Cap:5.59M
PE:-0.85
High:1.85
Open:1.72
Low:1.52
Close:1.68
52wk High:14.77
52wk Low:1.52
Shares:3.39M
Float Shares:1.69M
Volume Ratio:1.29
T/O Rate:4.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9469
EPS(LYR):-2.0691
ROE:-113.96%
ROA:-66.91%
PB:1.33
PE(LYR):-0.80

Loading ...

Company Profile

Company Name:
Kairos Pharma, Ltd.
Exchange:
AMEX
Establishment Date:
2013
Employees:
- -
Office Location:
2355 Westwood Blvd.,Suite 139,Los Angeles,California,United States
Zip Code:
90064
Fax:
- -
Introduction:
Kairos Pharma, Ltd. was originally incorporated under California law on June 17, 2013 as NanoGB13, Inc., and later converted to a Delaware corporation under the name Kairos Pharma, Ltd. on May 10, 2023. The company is a clinical-stage biopharmaceutical company dedicated to providing treatments for cancer patients, aiming to overcome key barriers in immunosuppression and drug resistance. Its therapies include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Directors

Name
Position
John S. Yu
Chairman of the Board and Chief Executive Officer and Director
Hansoo Michael Keyoung
Independent Director
Hyun W. Bae
Independent Director
Rahul Singhvi
Independent Director

Shareholders

Name
Position
John S. Yu
Chairman of the Board and Chief Executive Officer and Director
Doug Samuelson
Chief Financial Officer
Neil Bhowmick
Chief Scientific Officer
Ramachandran Murali
Vice President of Research and Development